Literature DB >> 17599809

Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene.

Liang Huo1, Richard E Straub, Catherine Roca, Peter J Schmidt, Kai Shi, Radhakrishna Vakkalanka, Daniel R Weinberger, David R Rubinow.   

Abstract

BACKGROUND: Premenstrual dysphoric disorder (PMDD) is a heritable mood disorder that is triggered by gonadal steroids during the luteal phase in susceptible women.
METHODS: We performed haplotype analyses of estrogen receptors alpha and beta (ESR1 and ESR2) in 91 women with prospectively confirmed PMDD and 56 control subjects to investigate possible sources of the genetic susceptibility to affective dysregulation induced by normal levels of gonadal steroids. We also examined associations with the valine (Val)158methionine (Met) single nucleotide polymorphism (SNP) of the gene for catechol-O-methyltransferase (COMT), an enzyme involved in estrogen metabolism and prefrontal cortical activation.
RESULTS: Four SNPs in intron 4 of ESR1 showed significantly different genotype and allele distributions between patients and control subjects. Significant case-control differences were seen in sliding-window analyses of two-, three-, and four-marker haplotypes but only in those haplotypes containing SNPs in intron 4 that were positive in the single-locus analysis. No significant associations were observed with ESR2 or with the COMT Val158Met polymorphism, although the significant associations with ESR1 were observed only in those with the Val/Val genotype.
CONCLUSIONS: These are the first positive (albeit preliminary) genetic findings in this reproductive endocrine-related mood disorder and involve the receptor for a hormone that is pathogenically relevant.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17599809      PMCID: PMC2762203          DOI: 10.1016/j.biopsych.2006.12.019

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  57 in total

1.  Operationalizing DSM-IV criteria for PMDD: selecting symptomatic and asymptomatic cycles for research.

Authors:  Mark J Smith; Peter J Schmidt; David R Rubinow
Journal:  J Psychiatr Res       Date:  2003 Jan-Feb       Impact factor: 4.791

Review 2.  The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD).

Authors:  Uriel Halbreich; Jeff Borenstein; Terry Pearlstein; Linda S Kahn
Journal:  Psychoneuroendocrinology       Date:  2003-08       Impact factor: 4.905

3.  GENECOUNTING: haplotype analysis with missing genotypes.

Authors:  Jing Hua Zhao; Sebastien Lissarrague; Laurent Essioux; Pak Chung Sham
Journal:  Bioinformatics       Date:  2002-12       Impact factor: 6.937

4.  Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene.

Authors:  A Heils; A Teufel; S Petri; M Seemann; D Bengel; U Balling; P Riederer; K P Lesch
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 5.  Gonadal steroid regulation of mood: the lessons of premenstrual syndrome.

Authors:  David R Rubinow; Peter J Schmidt
Journal:  Front Neuroendocrinol       Date:  2006-05-02       Impact factor: 8.606

6.  Serotonin transporter gene polymorphisms and platelet [3H] paroxetine binding in premenstrual dysphoria.

Authors:  J Melke; L Westberg; M Landén; C Sundblad; O Eriksson; F Baghei; R Rosmond; E Eriksson; A Ekman
Journal:  Psychoneuroendocrinology       Date:  2003-04       Impact factor: 4.905

7.  Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer.

Authors:  Yuichiro Tanaka; Masahiro Sasaki; Hiroaki Shiina; Takashi Tokizane; Masao Deguchi; Hiroshi Hirata; Yuji Hinoda; Naoko Okayama; Yutaka Suehiro; Shinji Urakami; Toshifumi Kawakami; Masanori Kaneuchi; Deepa Pookot; Mikio Igawa; Akihiko Okuyama; Nobuhisa Ishii; Rajvir Dahiya
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-02       Impact factor: 4.254

Review 8.  Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond.

Authors:  Elizabeth M Tunbridge; Paul J Harrison; Daniel R Weinberger
Journal:  Biol Psychiatry       Date:  2006-02-14       Impact factor: 13.382

9.  Strain differences in tamoxifen sensitivity of Sprague-Dawley and Fischer 344 rats.

Authors:  Jason A Bailey; Kenneth P Nephew
Journal:  Anticancer Drugs       Date:  2002-10       Impact factor: 2.248

10.  Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction.

Authors:  Avshalom Caspi; Terrie E Moffitt; Mary Cannon; Joseph McClay; Robin Murray; HonaLee Harrington; Alan Taylor; Louise Arseneault; Ben Williams; Antony Braithwaite; Richie Poulton; Ian W Craig
Journal:  Biol Psychiatry       Date:  2005-05-15       Impact factor: 13.382

View more
  44 in total

Review 1.  Gynecological management of premenstrual symptoms.

Authors:  Lee P Shulman
Journal:  Curr Pain Headache Rep       Date:  2010-10

Review 2.  A review of estrogen receptor alpha gene (ESR1) polymorphisms, mood, and cognition.

Authors:  Erin E Sundermann; Pauline M Maki; Jeffrey R Bishop
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

3.  Estrogen receptor alpha (ESR-1) associations with psychological traits in women with PMDD and controls.

Authors:  Alexandra Miller; Hoa Vo; Liang Huo; Catherine Roca; Peter J Schmidt; David R Rubinow
Journal:  J Psychiatr Res       Date:  2010-02-20       Impact factor: 4.791

4.  Increased childhood abuse in patients with premenstrual dysphoric disorder in a Turkish sample: a cross-sectional study.

Authors:  Esra Akyol Soydas; Yakup Albayrak; Basak Sahin
Journal:  Prim Care Companion CNS Disord       Date:  2014-07-24

Review 5.  Reproductive Affective Disorders: a Review of the Genetic Evidence for Premenstrual Dysphoric Disorder and Postpartum Depression.

Authors:  Katherine McEvoy; Lauren M Osborne; Julie Nanavati; Jennifer L Payne
Journal:  Curr Psychiatry Rep       Date:  2017-10-30       Impact factor: 5.285

6.  Premenstrual dysphoric disorder: burden of illness and treatment update.

Authors:  Teri Pearlstein; Meir Steiner
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

7.  Lifetime discrimination associated with greater likelihood of premenstrual dysphoric disorder.

Authors:  Corey E Pilver; Rani Desai; Stanislav Kasl; Becca R Levy
Journal:  J Womens Health (Larchmt)       Date:  2011-06       Impact factor: 2.681

Review 8.  Polymorphisms of estrogen receptors and risk of depression: therapeutic implications.

Authors:  Joanne Ryan; Marie-Laure Ancelin
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

9.  Differences in free estradiol and sex hormone-binding globulin in women with and without premenstrual dysphoric disorder.

Authors:  Susan Thys-Jacobs; Don McMahon; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2007-10-23       Impact factor: 5.958

10.  The complexity of premenstrual dysphoric disorder--risk factors in the population of Polish women.

Authors:  Violetta Skrzypulec-Plinta; Agnieszka Drosdzol; Krzysztof Nowosielski; Ryszard Plinta
Journal:  Reprod Biol Endocrinol       Date:  2010-11-14       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.